No Detail Found!

Efficacy of Filgrastim in Managing Chemotherapy-Induced Febrile Neutropenia in Iraqi Patients with Non-Small Cell Lung Cancer

Author(s)
Fatima Adnan Alzubaidi Department of Clinical Pharmacy, College of Pharmacy, University of Babylon, Babylon, Iraq
Enass Najem Oubaid Department of Pharmacognosy and medicinal plants, College of Pharmacy, University of Babylon, Babylon, Iraq
Ammar A. H. Azzam Department of Pharmacognosy and medicinal plants, College of Pharmacy, University of Babylon,Babylon,Iraq
Mohammed Sh. Sachit Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq
Hiba Falih abdulhussien Department of Pharmacognosy and medicinal plants, College of Pharmacy, University of Babylon,Babylon,Iraq
Fatima Mohammed hadi Department of Pharmacognosy and medicinal plants, College of Pharmacy, University of Babylon,Babylon,Iraq
Saif M. Hassan Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq
Abstract
Filgrastim, a recombinant human granulocyte colony-stimulating factor, has been intensively researched as a systemic treatment for neutropenia, notably in cancer patients receiving myelosuppressive chemotherapy. The use of filgrastim has demonstrated considerable benefits in reducing the frequency and duration of febrile neutropenia, as well as in supporting the maintenance of chemothera-py dose intensity. The research findings that multiple doses regime of filgrastim has significant benefits observed in reducing the incidence and duration of fe-brile neutropenia, as well as in supporting the maintenance of chemotherapy dose intensity, highlight its valuable role in improving the quality of life and treatment outcomes for patients undergoing myelosuppressive chemotherapy. In conclusion, the research on multiple doses regime of filgrastim provides solid evidence for its usefulness in controlling neutropenia-related problems in cancer patients
Publication Details
Page(s) 1744-1749
Published Journal: Pakistan Journal of Life and Social Sciences, Volume: 22, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
NSCLC Neutropenia Filgrastim, chemotherapy Granulocyte colony-stimulating factor
References
Serifoglu I,Sen N. Lung,Cancer N. Lung .2023 .Emergencies. , : 1-51.
Rapoport BL,Cooksley T,Johnson DB,Anderson R,Shannon VR .2021 .Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert review of clinical pharmacology. , 14(3) : 295-313.
Lyman GH,Kuderer NM,Aapro M. . .Improving outcomes of chemotherapy: established and novel options for myeloprotection in the COVID-19 era. , : .
Lantuejoul S,Fernandez-Cuesta L,Damiola F,Girard N,McLeer A .2020 .New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Translational Lung Cancer Research, 9(5) : 2233.
Lazarus DR,Strange CD,Ahuja J,Shroff GS,Sabloff BS,de Groot PM .2023 .Non-Small Cell Carcinoma. , : 311-72.
.2021 .New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. Hematology, 26(1) : 628-36.
Suzuki K,Yamada M,Kurakake S,Okamura N,Yamaya K,Liu Q .2000 .Circulating cytokines and hormones with immunosuppressive but neutrophil-priming potentials rise after endurance exercise in humans. European journal of applied physiology, 81 : 281-7.
Hobbs J,Lowe J,Ferdinand A,Shook A,Beck B,Blais D .2023 .Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis. Journal of Oncology Pharmacy Practice, 29(8) : 1853-61.
Clemons M,Fergusson D,Joy AA,Thavorn K,Meza-Junco J,Hiller JP .2021 .A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. The Breast, 58 : 42-9.
Lazarus HM,Ragsdale CE,Gale RP,Lyman GH .2021 .Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time? Frontiers in immunology. , 12 : 706186.
Li N,Huang C,Zhang J,Zhang J,Huang J,Li S .2023 .Chemotactic NO/H2S nanomotors realizing cardiac targeting of G-CSF against myocardial ischemia-reperfusion injury. ACS nano, 17(13) : 12573-93.
Clemons M,Fergusson D,Simos D,Mates M,Robinson A,Califaretti N .2020 .A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Annals of Oncology, 31(7) : 951-7.
Najafi S,Ansari M,Kaveh V,Haghighat S. Comparing .2021 .the efficacy and side-effects of PDLASTA®(Pegfilgrastim) with PDGRASTIM®(Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial. BMC cancer, 21 : 1-12.
Jam F. A.,Singh S. K. G.,Ng B.,Aziz N. .2018 .The interactive effect of uncertainty avoidance cultural values and leadership styles on open service innovation: A look at malaysian healthcare sector. International Journal of Business and Administrative Studies, 4(5) : 208-223.
Kanval N.,Ihsan H.,Irum S.,Ambreen I. .2024 .Human Capital Formation, Foreign Direct Investment Inflows, and Economic Growth: A Way Forward to Achieve Sustainable Development. Journal of Management Practices, Humanities and Social Sciences, 8(3) : 48-61.
0

Citations

0

Downloads

73

Views